AbbVie Inc (ABBV) : Hochman Cole Investment Advisors scooped up 216 additional shares in AbbVie Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Apr 11, 2016. The investment management firm now holds a total of 39,796 shares of AbbVie Inc which is valued at $2,368,260.AbbVie Inc makes up approximately 2.00% of Hochman Cole Investment Advisors’s portfolio.
AbbVie Inc opened for trading at $59.55 and hit $59.74 on the upside on Friday, eventually ending the session at $59.51, with a gain of 0.39% or 0.23 points. The heightened volatility saw the trading volume jump to 46,60,835 shares. Company has a market cap of $95,885 M.
Other Hedge Funds, Including , Grassi Investment Management reduced its stake in ABBV by selling 630 shares or 0.46% in the most recent quarter. The Hedge Fund company now holds 135,075 shares of ABBV which is valued at $8,038,313. AbbVie Inc makes up approx 1.57% of Grassi Investment Management’s portfolio.Charter Trust Co reduced its stake in ABBV by selling 383 shares or 0.24% in the most recent quarter. The Hedge Fund company now holds 160,376 shares of ABBV which is valued at $9,381,996. AbbVie Inc makes up approx 1.15% of Charter Trust Co’s portfolio.Filament reduced its stake in ABBV by selling 550 shares or 9.4% in the most recent quarter. The Hedge Fund company now holds 5,300 shares of ABBV which is valued at $310,050. AbbVie Inc makes up approx 0.15% of Filament’s portfolio.Thompson Rubinstein Investment Management Inc Or boosted its stake in ABBV in the latest quarter, The investment management firm added 25,226 additional shares and now holds a total of 72,240 shares of AbbVie Inc which is valued at $4,226,040. AbbVie Inc makes up approx 1.74% of Thompson Rubinstein Investment Management Inc Or’s portfolio.Weaver C. Barksdale Associates reduced its stake in ABBV by selling 102 shares or 0.67% in the most recent quarter. The Hedge Fund company now holds 15,117 shares of ABBV which is valued at $884,345. AbbVie Inc makes up approx 0.67% of Weaver C. Barksdale Associates’s portfolio.
On the company’s financial health, AbbVie Inc reported $1.13 EPS for the quarter, beating the analyst consensus estimate by $ 0.01 according to the earnings call on Jan 29, 2016. Analyst had a consensus of $1.12. The company had revenue of $6400.00 million for the quarter, compared to analysts expectations of $6382.82 million. The company’s revenue was up 17.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.89 EPS.
Many Wall Street Analysts have commented on AbbVie Inc. Societe Generale Initiated AbbVie Inc on Apr 6, 2016 to “Sell”, Price Target of the shares are set at $47.Deutsche Bank Initiated AbbVie Inc on Mar 15, 2016 to “Hold”, Price Target of the shares are set at $63.AbbVie Inc was Upgraded by Citigroup to ” Buy” on Feb 23, 2016.
AbbVie Inc. (AbbVie) is a global research-based biopharmaceutical company. The Company develops and markets therapies that address a range of diseases. The Company’s products are focused on treating conditions such as chronic autoimmune diseases including rheumatoid arthritis psoriasis and Crohn’s disease; hepatitis C (HCV); human immunodeficiency virus (HIV); endometriosis; thyroid disease; Parkinson’s disease; complications associated with chronic kidney disease and cystic fibrosis and other health conditions such as low testosterone. AbbVie also has a pipeline of new medicines including over 30 compounds or indications in Phase II or Phase III development across a range of medical specialties such as immunology virology/liver disease oncology renal disease neurological diseases and women’s health. The Company’s product portfolio includes HUMIRA HCV products Additional Virology products Metabolics/Hormones products Endocrinology products and other products.